PIK3CA and neoplasm: This extended overall survival was confirmed in a recent update report which showed an 8-month improvement in median overall survival with alpelisib plus fulvestrant versus fulverstrant monotherapy in patients with PIK3CA-mutated tumours (although the findings did not cross the pre-specified boundary for statistical significance) [60].